Gene chimeric human adenovirus and its construction method and application
Through the construction of genetic chimeric human adenovirus, the problems of safety risks and limited use of existing adenovirus vaccines have been solved, and the attenuation and efficient expression of adenoviruses are achieved, providing a safe and effective vaccine and genetically modified therapy vector. .
Patent Information
- Application Number
- CN202311576004.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-24
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-11-24
AI Technical Summary
Existing adenovirus vaccines have safety risks and limited use, especially the risk of live virus contamination in the environment is high, and there is a lack of safe and effective research on attenuated adenovirus vaccines.
Through the construction of a gene chimeric human adenovirus, the specific method includes replacing the E4orf6 region of the target human adenovirus with the E4orf6 region of HAd5, and inserting an exogenous gene expression box in the E3 region to prepare a gene chimeric human adenovirus. Such as Ad7-dE3E-A5E4, the virus is attenuated and efficiently expressed.
Achieve significant attenuation of the chimeric human adenovirus, improves safety and scope of use, can be used as a vaccine vector and a transgenic therapy vector, with more efficient exogenous gene expression and lower cost, suitable for commonly used HEK Prepared in -293 cells.
Smart Images

Figure CN117821405B_ABST
Abstract
Citation Information
Cited By
Construction method and application of adenovirus infected animal model
CN121753758A
